Pulse oximeters, the clip-on devices widely used in hospitals and homes across the United States to monitor blood oxygen saturation, can overestimate oxygen levels in patients with darker skin pigmentation. Clinical evaluations and federal safety alerts warn that because these monitors rely on light absorption through tissue, higher melanin levels can interfere with the optical sensors and conceal dangerously low oxygen levels, a condition known as occult hypoxemia.
The concern gained national traction following a landmark 2020 study in the New England Journal of Medicine and subsequent U.S. Food and Drug Administration (FDA) communications in February 2021 and on January 7, 2025. While health authorities emphasize that pulse oximeters remain useful tools for tracking respiratory trends, clinicians and patients are urged to interpret displayed numbers alongside physical symptoms rather than relying on a single reading to rule out low oxygen.
How Light-Absorption Technology Creates Disparities
Unlike an arterial blood gas test, which measures oxygen directly from a blood sample drawn from an artery, a pulse oximeter provides a noninvasive estimate of peripheral oxygen saturation, or SpO2. The device shines specific wavelengths of light through a fingertip or earlobe and calculates oxygen levels based on how much light is absorbed by hemoglobin in the blood. Because melanin in the skin also absorbs light, higher skin pigmentation can alter the sensor's optical calculations.
According to Diagnostics World News, the 2020 New England Journal of Medicine study compared pulse oximeter readings directly with arterial blood gas measurements and found that occult hypoxemia occurred more frequently in Black patients than in White patients. In the summarized findings, occult hypoxemia was defined as a true arterial oxygen saturation below 88% at a time when the pulse oximeter displayed a seemingly reassuring SpO2 reading between 92% and 96%.
Data compiled by PeptideAI highlights the scale of the gap observed in those hospital evaluations. In a Michigan cohort analyzed in the 2020 research, occult hypoxemia appeared in 11.7% of readings among Black patients compared with 3.6% of readings among White patients. In a separate multicenter cohort from the same study, hidden low oxygen occurred in 17.0% of readings in Black patients versus 6.2% in White patients.
Researchers and medical reviewers note differing perspectives on how broadly these figures apply outside the hospital. While clinical evaluations clearly demonstrate a higher rate of missed hypoxemia among Black patients when readings fall into an apparently acceptable range, analysts at PeptideAI and Diagnostics World News point out that these percentages are study-specific estimates rather than universal, population-wide probabilities. Error rates vary substantially depending on the specific patient group, the device model, and the exact threshold used to define low oxygen.
Federal Scrutiny and Updated Testing Standards
The clinical findings prompted federal regulators to re-examine how pulse oximeters are evaluated before reaching the market. As reported by Diagnostics World News, historic FDA minimum premarket testing standards required manufacturers to evaluate devices on at least 10 subjects, with at least 15% of those participants having dark skin pigmentation—a benchmark that critics argued was too small to detect systematic bias across diverse populations.
In February 2021, the FDA issued a safety communication alerting healthcare providers and consumers that pulse oximeter accuracy can be limited by skin pigmentation as well as several physiological and environmental factors, according to GAMO. Beyond melanin levels, poor peripheral circulation, skin thickness, cold skin temperature, tobacco use, and dark fingernail polish can all distort light transmission and skew results.
Regulatory efforts continued to evolve. On January 7, 2025, the FDA issued draft guidance for medical-purpose pulse oximeters that addressed performance testing, product labeling, and premarket submission standards, according to E3 Learning. However, regulatory summaries from E3 Learning and PeptideAI note that while the draft recommendations signaled stronger oversight for clinical-grade monitors, available documentation does not confirm whether the guidance has been finalized into a binding rule or whether those standards apply equally to over-the-counter consumer wellness gadgets.
What This Means for Patients Using Home Monitors
For individuals monitoring respiratory conditions at home, health educators emphasize that a pulse oximeter provides an estimate rather than a definitive diagnosis. While study evidence and FDA summaries confirm that darker pigmentation is associated with a risk of overestimated readings, guidance from Chutex Innovation underscores that not every device consistently overestimates oxygen for every person with darker skin. Because variance differs by user and situation, patients should never attempt to apply a fixed mathematical correction—such as subtracting a set number of percentage points—to their home readings.
Instead, medical guidance advises tracking trends over time under consistent measurement conditions. Users can improve reading reliability by resting quietly before testing, warming cold hands, removing fingernail polish, and keeping the hand still below heart level. Above all, a reassuring number on a screen should never override physical signs of respiratory distress.
Frequently Asked Questions
Do findings from hospital cohorts translate directly to over-the-counter wellness devices?
Not necessarily. The strongest evidence linking skin pigmentation to missed hypoxemia comes from hospital settings where prescription-grade oximeters were compared directly against arterial blood gas draws. Over-the-counter wellness devices and smartwatches are not always held to the same premarket review standards as medical-purpose monitors, meaning their real-world accuracy across different skin tones can vary even more widely by model.
Have the FDA's January 2025 draft recommendations been finalized?
Current regulatory summaries confirm that the FDA released draft guidance on January 7, 2025, proposing updated premarket testing and labeling expectations for medical-purpose pulse oximeters. However, reviewed public summaries do not verify that those draft recommendations have been finalized into mandatory federal regulations.
Which symptoms and conditions should prompt a medical evaluation even if a home reading looks normal?
According to Chutex Innovation and GAMO, patients should seek prompt clinical assessment if they experience shortness of breath at rest, difficulty breathing after minimal exertion, chest pain, persistent dizziness, confusion, rapid heart rate, or bluish discoloration around the lips, tongue, or nail beds—even if a home oximeter displays a reading between 92% and 96%.
